Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine

  • Castellsagué, Joan|||0000-0002-2579-3137
  • Gel, Bernat|||0000-0001-8878-349X
  • Fernández-Rodríguez, Juana
  • Llatjós, Roger
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Pérez-Sidelnikova, Diana
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Viñals, Joan Maria
  • Vidal, August|||0000-0001-5727-2099
  • Valdés-Mas, Rafael
  • Terribas, Ernest
  • López-Doriga, Adriana
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Capella, Gabriel|||0000-0002-4669-7320
  • Puente, Xose S.|||0000-0001-9525-1483
  • Serra, Eduard|||0000-0003-2895-9857
  • Villanueva Garatachea, Alberto
  • Lázaro García, Conxi|||0000-0002-7198-5906
Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that can arise either sporadically or in association with neurofibromatosis type 1 (NF1). These aggressive malignancies confer poor survival, with no effective therapy available. We present the generation and characterization of five distinct MPNST orthoxenograft models for preclinical testing and personalized medicine. Four of the models are patient-derived tumor xenografts (PDTX), two independent MPNSTs from the same NF1 patient and two from different sporadic patients. The fifth model is an orthoxenograft derived from an NF1-related MPNST cell line. All MPNST orthoxenografts were generated by tumor implantation, or cell line injection, next to the sciatic nerve of nude mice, and were perpetuated by 7-10 mouse-to-mouse passages. The models reliably recapitulate the histopathological properties of their parental primary tumors. They also mimic distal dissemination properties in mice. Human stroma was rapidly lost after MPNST engraftment and replaced by murine stroma, which facilitated genomic tumor characterization. Compatible with an origin in a catastrophic event and subsequent genome stabilization, MPNST contained highly altered genomes that remained remarkably stable in orthoxenograft establishment and along passages. Mutational frequency and type of somatic point mutations were highly variable among the different MPNSTs modeled, but very consistent when comparing primary tumors with matched orthoxenografts generated. Unsupervised cluster analysis and principal component analysis (PCA) using an MPNST expression signature of ~1,000 genes grouped together all primary tumor-orthoxenograft pairs. Our work points to differences in the engraftment process of primary tumors compared with the engraftment of established cell lines. Following standardization and extensive characterization and validation, the orthoxenograft models were used for initial preclinical drug testing. Sorafenib (a BRAF inhibitor), in combination with doxorubicin or rapamycin, was found to be the most effective treatment for reducing MPNST growth. The development of genomically well-characterized preclinical models for MPNST allowed the evaluation of novel therapeutic strategies for personalized medicine.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia

  • Anadón, C.
  • van Tetering, G.
  • Ferreira, H. J.
  • Moutinho, Catia|||0000-0003-3885-0847
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Soler, Marta|||0000-0002-6656-957X
  • Heyn, Holger|||0000-0002-3276-1889
  • Moran, S.|||0000-0003-4192-8983
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Setien, F.
  • Vidal, A.
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Guil, Sonia|||0000-0002-2257-3331
  • Esteller, M.|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Matito, Judit|||0000-0001-7560-7737
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Navarro, Alejandro|||0000-0001-5903-270X
  • Cedrés, Susana|||0000-0002-0648-7978
  • Pardo Aranda, Nuria
  • Martinez de Castro, Ana
  • Remon, Jordin
  • Miquel, J. M.
  • Guillaumet-Adkins, A.
  • Nadal, Ernest|||0000-0002-9674-5554
  • Rodriguez Esteban, Gustavo
  • Arqués Casamitjana, Oriol
  • Fasani, Roberta|||0000-0003-1630-9988
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Heyn, Holger|||0000-0002-3276-1889
  • Villanueva Garatachea, Alberto
  • Palmer, Héctor G.
  • Vivancos, Ana|||0000-0003-2888-6512
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. Different mechanisms of acquired resistance to third-generation EGFR-TKIs have been proposed. It is therefore crucial to identify new and effective strategies to overcome successive acquired mechanisms of resistance. For Amplicon-seq analysis, samples from the index patient (primary and metastasis lesions at different timepoints) as well as the patient-derived orthotopic xenograft tumors corresponding to the different treatment arms were used. All samples were formalin-fixed paraffin-embedded, selected and evaluated by a pathologist. For droplet digital PCR, 20 patients diagnosed with NSCLC at baseline or progression to different lines of TKI therapies were selected. Formalin-fixed paraffin-embedded blocks corresponding to either primary tumor or metastasis specimens were used for analysis. For single-cell analysis, orthotopically grown metastases were dissected from the brain of an athymic nu/nu mouse and cryopreserved at -80°C. In a brain metastasis lesion from a NSCLC patient presenting an EGFR T790M mutation, we detected MET gene amplification after prolonged treatment with osimertinib. Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis. In those mice treated with capmatinib or afatinib as monotherapy, we observed the emergence of KRAS G12C clones. Single-cell gene expression analyses also revealed intratumor heterogeneity, indicating the presence of a KRAS -driven subclone. We also detected low-frequent KRAS G12C alleles in patients treated with various EGFR-TKIs. Acquired resistance to subsequent EGFR-TKI treatment lines in EGFR -mutant lung cancer patients may induce genetic plasticity. We assess the biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET- amplification and propose new treatment strategies in this situation.